Please use this identifier to cite or link to this item:
Title: Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling
Authors: Shen, J.
Tai, Y.-C. 
Zhou, J. 
Stephen, Wong C.-H. 
Xie, Z. 
Chen, C.-S. 
Cheang, P.T.S. 
Han, J.-H. 
Fred, Wong W.-S. 
Khan, M. 
Issue Date: 2007
Citation: Shen, J.,Tai, Y.-C.,Zhou, J.,Stephen, Wong C.-H.,Xie, Z.,Chen, C.-S.,Cheang, P.T.S.,Han, J.-H.,Fred, Wong W.-S.,Khan, M. (2007). Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Experimental Hematology 35 (1). ScholarBank@NUS Repository.
Abstract: We investigated the antiproliferative effect of genistein, and its antileukemia effect in combination with cytosine arabinoside (ara-C) in acute myeloid leukemia (AML). Optimal dosage of genistein as single agent and in combination with ara-C was first determined in vitro. Genistein demonstrated a dose- and time-dependent inhibition of cell proliferation, induction of apoptosis, and cell-cycle arrest at G2/M phase. Gene-expression profiles revealed mitogen-activated protein kinase (MAPK) signaling as one of the most affected biological pathways. Phosphatidylinositol 3 kinase, protein kinase A, protein kinase C, MAPK kinase 4, KIT, PIM1, and transforming growth factor-β receptor 1, were significantly downregulated by genistein. To test whether genistein could augment the antiproliferation activity of ara-C, two groups of severe combined immunodeficient mice were inoculated with NB4 and HL-60 cells, respectively, followed by treatment with either genistein or combination of genistein and ara-C. The combination treatment significantly inhibited tumor growth, and improved survival of NB4 (p = 0.0031) and HL-60 (p = 0.0007) xenograft mice. Our present study highlighted the schedule-dependent synergistic antileukemia effect of genistein with chemotherapy in both in vitro and in vivo models. This novel combination could potentially be a promising regimen for treatment of AML. © 2007 International Society for Experimental Hematology.
Source Title: Experimental Hematology
ISSN: 0301472X
DOI: 10.1016/j.exphem.2006.09.007
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Apr 14, 2019

Page view(s)

checked on Apr 8, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.